- Home
- Automated
- NDF A-Z listing
- Emtricitabine + Tenofovir Alafenamide
E
Emtricitabine + Tenofovir Alafenamide
Subsidy Information and Financing Scheme
No
Drug Guidance
Yes
Post-marketing information
No
Summary of Biologics
No
Active ingredients: Emtricitabine | Tenofovir
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended the following antiretroviral therapies (ARTs):
Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs): lamivudine 150 mg tablet, tenofovir disoproxil fumarate 300 mg tablet, zidovudine 100 mg capsule;
Non-nucleoside reverse transcriptase inhibitors (NNRTIs): efavirenz 200 mg and 600 mg tablets, etravirine 200 mg tablet, nevirapine 200 mg and 400 mg tablets, rilpivirine 25 mg tablet;
Protease inhibitors (PIs): atazanavir 200 mg and 300 mg capsules, darunavir 600 mg and 800 mg tablets, lopinavir 200 mg/ritonavir 50 mg tablet and lopinavir 80 mg/ritonavir 20 mg oral solution, ritonavir 100 mg tablet;
Integrase strand transfer inhibitors (INSTIs): dolutegravir 50 mg tablet, raltegravir 400 mg and 600 mg tablets; and
Fixed-dose combinations: abacavir 600 mg/lamivudine 300 mg tablet, abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg tablet, emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet
in line with their registered indications for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection.
Subsidy status
[R] Raltegravir 400 mg and 600 mg tablets, and emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet are recommended for inclusion on the Medication Assistance Fund (MAF) in combination with other antiretroviral agents for the treatment of HIV-1 infection.
[R] All other abovementioned ARTs are recommended for the inclusion on the MOH Standard Drug List (SDL).
[NR] SDL subsidy or MAF assistance do not apply to any other ARTs that are not listed above.
Details of all recommendations are provided in the Annex.
Legend
This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.
Legend list
Indicator | Legend |
|---|---|
R | Recommended for subsidy |
NR | Not recommended for subsidy |
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |